jupiter: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin

principal researchers

Robert Glynn (Harvard T.H. Chan School of Public Health)

Paul M Ridker (Brigham and Women's Hospital, Harvard Medical School)   

data custodian

JUPITER Investigators

funding

AstraZeneca

key publications

• Design paper: Circulation 2003; 108: 2292-2297
• Main results: N Engl J Med 2008; 359: 2195-207
• Reduction in CRP and LDL-C and CV event rates: Lancet 2009; 373:1175-82
• Prevention of venous thromboembolism:  N Engl J Med 2009; 360:1851-61
• Justification for use of statins in prevention:  Circulation 2010; 121:143-50
• Effects in women: Circulation 2010; 121:1069-77
• Effects in older people: Ann Intern Med 2010; 152:488-96
• HDL-C and residual risk of first CV events: Lancet 2010; 376:333-9
• Cost effectiveness: Journal of Medical Economics 2010; 13(3): 428-37
• Use of Statins in Prevention: J Am Coll Cardiol 2011; 57:1666-75
• Effect on hemoglobin levels:  J Clin Pharmacol 2011; 51(10): 1483-7
• Efficacy in older people:  Ann Intern Med 2010; 152(8): 488-96
• Ethnicity:  American Heart Journal 2011; 162 (1); 106-14 Efficacy and safety in those attaining LDL-C <50mg/dL: J Am Coll Cardiol 2011; 57(16):1666-75
• CV benefits and diabetes risks of statins in primary prevention: Lancet 2012; 380:565-71
• Safety profile in those treated to LDL-C <30mg/dL: Am J Cardiol 2014; 114(11):1682-9
• Risk of fracture:  JAMA Intern Med 2015; 175(2) 171-7
• Genetic risk, CHD events and clinical benefit: Lancet 2015; 385:2264-71